Health and Healthcare

Array BioPharma Rallies on Late-Stage Win

Chris Lange

Published: December 16, 2015 8:45 am

Last Updated: January 13, 2020 4:02 pm

Array BioPharma Inc. (NASDAQ: ARRY) led the bulls early on Monday on news of a positive late-stage clinical trial. The company reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study met its primary endpoint of improving progression-free survival (PFS) compared with dacarbazine treatment.

In the trial, binimetinib was generally well-tolerated and the adverse events reported were consistent with previous results in NRAS melanoma patients.

Binimetinib is also being studied in the Phase 3 Columbus trial for patients with BRAF-mutant melanoma and the Phase 3 Milo trial for patients with low grade serous ovarian cancer, as well as in several other earlier stage clinical trials.

Ron Squarer, CEO of Array BioPharma, said:

We are excited to announce positive results from the NEMO trial, which suggest binimetinib has the potential to provide an important new treatment option for patients with advanced NRAS melanoma. We look forward to discussing the data with the FDA and other regulatory agencies in the near future.

24/7 Wall St.
The Most (and Least) Healthy States: A Survey of All 50